Literature DB >> 27135

A disorder of biogenic amines in dihydropteridine reductase deficiency.

I J Butler, S H Koslow, A Krumholz, N A Holtzman, S Kaufman.   

Abstract

A severe deficiency of dihydropteridine reductase (DHPR) in liver, brain, and cultured skin fibroblasts was demonstrated in a child with hyperphenylalaninemia and an atypical form of phenylketonuria. DHPR is required for regeneration of the cofactor, tetrahydrobiopterin. The cofactor is essential in hydroxylation of aromatic amino acid precursors in the biosynthesis of neurotransmitters, serotonin, dopamine, and norepinephrine. In gray tissue at brain biopsy, dopamine was low at 3 ng per gram of tissue, serotonin was barely detected, and norepinephrine appeared high at 1600 ng per gram. In cerebrospinal fluid, homovanillic acid (HVA) was low normal at 33 ng/ml, 5-hydroxyindoleacetic acid (5-HIAA) was low at 4.2 ng/ml, and after a high dose of oral probenecid there was impaired accumulation of HVA to 128 ng/ml and 5-HIAA to 22.4 ng/ml. When the patient was 22 months of age, treatment with hydroxylated aromatic amino acid precursors was initiated, and after three months HVA and 5-HIAA levels were increased in CSF. The apparent restoration of biogenic amines in brain appears to have delayed the rate of neurological deterioration. DHPR activity in cultured skin fibroblasts of children with persistent hyperphenylalaninemia should permit early diagnosis and early treatment of this disorder.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 27135     DOI: 10.1002/ana.410030307

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  14 in total

1.  Biomolecular information analysis in neurotransmitter systems.

Authors:  S C Brooks
Journal:  Acta Biotheor       Date:  1984       Impact factor: 1.774

2.  Tetrahydrobiopterin and quinonoid dihydrobiopterin concentrations in CSF from patients with dihydropteridine reductase deficiency.

Authors:  K Hyland; S J Heales
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

3.  Hyperphenylalaninemia due to impaired dihydrobiopterin biosynthesis.

Authors:  T Tanaka; K Aihara; K Iwai; M Kohashi; K Tomita; K Narisawa; N Arai; H Yoshida; T Usui
Journal:  Eur J Pediatr       Date:  1981-07       Impact factor: 3.183

4.  Diagnosis of malignant hyperphenylalaninaemia.

Authors:  D M Danks; R G Cotton; P Schlesinger
Journal:  Arch Dis Child       Date:  1979-05       Impact factor: 3.791

5.  Neuroblastoma in a patient with dihydropteridine reductase deficiency.

Authors:  L G Greeves; R J Leeming; K Hyland; S I Dempsey; D J Carson
Journal:  Eur J Pediatr       Date:  1990-07       Impact factor: 3.183

Review 6.  Some metabolic relationships between biopterin and folate: implications for the "methyl trap hypothesis".

Authors:  S Kaufman
Journal:  Neurochem Res       Date:  1991-09       Impact factor: 3.996

7.  Biopterin synthesis defect. Treatment with L-dopa and 5-hydroxytryptophan compared with therapy with a tetrahydropterin.

Authors:  R R McInnes; S Kaufman; J J Warsh; G R Van Loon; S Milstien; G Kapatos; S Soldin; P Walsh; D MacGregor; W B Hanley
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

8.  Atypical phenylketonuria with defective biopterin metabolism. Monotherapy with tetrahydrobiopterin or sepiapterin, screening and study of biosynthesis in man.

Authors:  A Niederwieser; H C Curtius; M Wang; D Leupold
Journal:  Eur J Pediatr       Date:  1982-03       Impact factor: 3.183

Review 9.  Pteridines and mono-amines: relevance to neurological damage.

Authors:  I Smith; D W Howells; K Hyland
Journal:  Postgrad Med J       Date:  1986-02       Impact factor: 2.401

10.  Dihydrobiopterin biosynthesis deficiency.

Authors:  J L Dhondt; B Leroux; J P Farriaux; C Largilliere; R J Leeming
Journal:  Eur J Pediatr       Date:  1983-12       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.